This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BROWN, E. M. Articles by AURBACH, G. D. Search for Related Content PubMed PubMed Citation Articles by BROWN, E. M. Articles by AURBACH, G. D.

Direct Comparison In Vivo and In Vitro of Suppressibility of Parathyroid Function by Calcium in Primary Hyperparathyroidism^*

Metabolic Diseases Branch, National Institute of Arthritis, Metabolism, and Digestive Diseases, (E.M.B., D.G.G., S.J.M., A.M.S., R.W.D., M.A., G.D.A.), and the Surgery Branch, National Cancer Institute (M.F.B.), National Institutes of Health, Bethesda, Maryland 20014; and the Division of Endocrinology, Department of Internal Medicine, Yale University (A.E.B.), New Haven, Connecticut 06510

The effects of increased ambient calcium concentration on parathyroid function in vivo and in vitro were assessed in each of 12 patients with primary hyperparathyroidism. Calcium injection and/or infusion were carried out preoperatively and parathyroid suppressibility was tested by the effect of calcium on nephrogenous cAMP (NcAMP). Dispersed parathyroid cells were then prepared after surgical excision of abnormal parathyroid tissue. Immunoreactive parathyroid hormone (iPTH) release was determined by RIA after incubation for 2 h at calcium concentrations ranging from 0.3-3.0 mM. Of nine patients with adenoma, iPTH release from dispersed parathyroid cells was inhibited less than 50% in 3 (26-40%); in these patients, NcAMP was suppressed 20% or less. In the remaining six patients, iPTH release in vitro and NcAMP release in vivo were inhibited 62-90% and 34-75%, respectively, by elevated calcium concentrations. In three patients with primary parathyroid hyperplasia, iPTH release was inhibited 75-81% and NcAMP release was inhibited 33-50%. Suppressibility of hormone release as a function of ionized calcium concentration generally showed agreement between in vivo and in vitro results for each patient. These results support the validity of these parameters, iPTH release from dispersed parathyroid cells and NcAMP, to assess secretory control in vivo and in vitro from abnormal parathyroid tissue. (J Clin Endocrinol Metab 48: 604, 1979)

^* This work was supported in part by a grant from the Kroc Foundation.

Received July 3, 1978.

This article has been cited by other articles:

				I. Titon, A. Cailleux-Bounacer, J. P. Basuyau, H. Lefebvre, A. Savoure, and J. M. Kuhn Evaluation of a standardized short-time calcium suppression test in healthy subjects: interest for the diagnosis of primary hyperparathyroidism Eur. J. Endocrinol., September 1, 2007; 157(3): 351 - 357. [Abstract] [Full Text] [PDF]

				S Bas, E Aguilera-Tejero, A Bas, J C Estepa, I Lopez, J A Madueno, and M Rodriguez The influence of the progression of secondary hyperparathyroidism on the set point of the parathyroid hormone-calcium curve J. Endocrinol., January 1, 2005; 184(1): 241 - 247. [Abstract] [Full Text] [PDF]

				C. C. Chow, W. B. Chan, J. K. Y. Li, N. N. Chan, M. H. M. Chan, G. T. C. Ko, K. W. Lo, and C. S. Cockram Oral Alendronate Increases Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 581 - 587. [Abstract] [Full Text] [PDF]

				F. Cetani, A. Picone, P. Cerrai, E. Vignali, S. Borsari, E. Pardi, P. Viacava, A. G. Naccarato, P. Miccoli, O. Kifor, et al. Parathyroid Expression of Calcium-Sensing Receptor Protein and in Vivo Parathyroid Hormone-Ca2+ Set-Point in Patients with Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4789 - 4794. [Abstract] [Full Text]

				C. P. Schmitt and F. Schaefer Calcium sensitivity of the parathyroid in renal failure: another look with new methodology Nephrol. Dial. Transplant., December 1, 1999; 14(12): 2815 - 2818. [Full Text] [PDF]

				M. T. Collins, M. C. Skarulis, J. P. Bilezikian, S. J. Silverberg, A. M. Spiegel, and S. J. Marx Treatment of Hypercalcemia Secondary to Parathyroid Carcinoma with a Novel Calcimimetic Agent J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1083 - 1088. [Abstract] [Full Text]